Hwang Katie L, Hwang William L, Bussière Marc R, Shih Helen A
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA.
Chin Clin Oncol. 2017 Jul;6(Suppl 1):S5. doi: 10.21037/cco.2017.06.09.
Meningiomas account for approximately one-third of primary central nervous system tumors with a subset that are aggressive and carry significant morbidity and mortality. Treatment of these high-grade meningiomas, classified by the World Health Organization as grade II (atypical) and grade III (anaplastic) meningiomas, typically includes the combination of surgery and radiotherapy. However, current data guiding the timing, dosage, and modality of radiation treatment (RT) has been limited to case series and retrospective studies. Nevertheless, most studies support that radiation therapy reduces recurrence risk and improves overall survival (OS) for patients with high-grade meningiomas. In this review, we examine the evidence for radiation therapy in the management of patients with atypical and anaplastic meningiomas and discuss current ongoing prospective trials that will further elucidate the optimal role of radiotherapy in the treatment of these aggressive tumors.
脑膜瘤约占原发性中枢神经系统肿瘤的三分之一,其中一部分具有侵袭性,会导致严重的发病率和死亡率。这些被世界卫生组织分类为II级(非典型)和III级(间变性)的高级别脑膜瘤的治疗通常包括手术和放疗相结合。然而,目前指导放射治疗(RT)的时机、剂量和方式的数据仅限于病例系列和回顾性研究。尽管如此,大多数研究支持放射治疗可降低高级别脑膜瘤患者的复发风险并提高总生存率(OS)。在本综述中,我们研究了放射治疗在非典型和间变性脑膜瘤患者管理中的证据,并讨论了当前正在进行的前瞻性试验,这些试验将进一步阐明放射治疗在这些侵袭性肿瘤治疗中的最佳作用。